Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:CRNXNASDAQ:GYRENASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$22.48-1.4%$23.94$14.75▼$26.58$2.74B0.721.10 million shs2.02 million shsCRNXCrinetics Pharmaceuticals$30.16-1.1%$31.44$24.10▼$62.53$2.82B0.28840,073 shs675,585 shsGYREGyre Therapeutics$8.07-3.1%$9.15$6.11▼$19.00$756.63M1.79124,941 shs148,306 shsHCMHUTCHMED$14.84-3.8%$14.64$11.51▼$21.50$2.59B0.52100,295 shs103,843 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%-4.46%-6.76%-7.22%+50.17%CRNXCrinetics Pharmaceuticals0.00%-5.07%+0.17%-12.38%-31.90%GYREGyre Therapeutics0.00%+1.00%-28.01%-16.89%-25.28%HCMHUTCHMED0.00%-12.19%+11.83%-1.00%-16.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9171 of 5 stars3.62.00.03.93.43.33.8CRNXCrinetics Pharmaceuticals3.2208 of 5 stars3.50.00.03.71.52.50.0GYREGyre Therapeutics0.6064 of 5 stars0.03.00.00.03.20.80.0HCMHUTCHMED1.83 of 5 stars3.02.00.00.01.30.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8346.06% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56147.20% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AHCMHUTCHMED 2.00Hold$19.0028.03% UpsideCurrent Analyst Ratings BreakdownLatest GYRE, HCM, CRNX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.58$2.45 per share9.19$6.10 per share3.69CRNXCrinetics Pharmaceuticals$1.04M2,715.27N/AN/A$14.29 per share2.11GYREGyre Therapeutics$105.76M7.15$0.20 per share40.86$1.05 per share7.69HCMHUTCHMED$630.20M4.10$0.29 per share51.67$4.43 per share3.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5714.3210.550.9236.91%42.45%36.59%8/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)GYREGyre Therapeutics$12.09M$0.02403.70∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.16N/AN/AN/AN/A7/29/2025 (Estimated)Latest GYRE, HCM, CRNX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.145.96CRNXCrinetics PharmaceuticalsN/A22.5322.53GYREGyre TherapeuticsN/A3.603.19HCMHUTCHMED0.082.832.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%GYREGyre Therapeutics23.99%HCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals4.60%GYREGyre Therapeutics10.00%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableGYRE, HCM, CRNX, and CPRX HeadlinesRecent News About These CompaniesHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?June 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Lowered to Buy Rating by Wall Street ZenJune 15, 2025 | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comHutchmed introduces new share options and LTIP awardsJune 11, 2025 | uk.investing.comHUTCHMED Grants Share Options and LTIP Awards to Boost Talent RetentionJune 10, 2025 | tipranks.comHUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" RatingJune 7, 2025 | marketbeat.comWall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?June 5, 2025 | zacks.comChina accepts NDA for sintilimab and fruquintinib combo in kidney cancerJune 5, 2025 | msn.comInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | prnewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Still a Buy?June 3, 2025 | marketbeat.comHUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer TreatmentJune 1, 2025 | tipranks.comHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual MeetingJune 1, 2025 | globenewswire.comMillennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)June 1, 2025 | marketbeat.comTrinity Delta Estimates HUTCHMED FY2025 EarningsMay 31, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 27, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 26, 2025 | marketbeat.comHUTCHMED to Present Promising Oncology Data at 2025 ASCO MeetingMay 22, 2025 | tipranks.comHUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual MeetingMay 22, 2025 | globenewswire.comJane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGYRE, HCM, CRNX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$22.48 -0.33 (-1.45%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$22.81 +0.33 (+1.47%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$30.16 -0.34 (-1.11%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$30.50 +0.34 (+1.13%) As of 06/20/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Gyre Therapeutics NASDAQ:GYRE$8.07 -0.26 (-3.12%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.07 +0.00 (+0.06%) As of 06/20/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$14.84 -0.59 (-3.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.83 -0.01 (-0.07%) As of 06/20/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
